readthroughSign in
Aug 13, 2026Trial update5 fact check notes

Voyager Therapeutics registers Phase 1 dose-escalation trial of VY1706 in early Alzheimer's disease

The company's first-in-human study of gene therapy candidate VY1706 was first posted on August 13, 2026, and is recruiting at a single U.S. site.

  • VY1706, an experimental gene therapy, entered a Phase 1 open-label dose-escalation study in participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. The trial is described as a first in human study in early Alzheimer's Disease1 and is listed as recruiting at K2 Medical Research, LLC, Maitland, Florida, United States1, the only site named in the record. The study plans to enroll 18 participants (estimated)1 across low, mid, and high dose IV infusion arms, with an estimated primary completion date of 2029-04-28 (estimated)1.

Fact check notes

  • ImpreciseThe study is described as the company's first-in-human study of gene therapy candidate VY1706The record confirms it's a first-in-human study but never explicitly labels VY1706 as a 'gene therapy'; this is inferred from AAV9-related exclusion criteria and assay, not stated outright.
  • ImpreciseVY1706 is an experimental gene therapyStrongly implied by AAV9-related screening/exclusion criteria but not explicitly stated as a gene therapy in the record.
  • Checker's noteThe entry asserts VY1706 is 'the company's lead Alzheimer's candidate' and that the entry was logged 'this week,' neither of which is supported by the source.
  • Checker's noteThe entry labels VY1706 explicitly as a 'gene therapy,' which is only inferable from AAV9-related screening/exclusion criteria, not directly stated in the record.
  • Sentence removedVoyager Therapeutics logged one new registry entry this week for its lead Alzheimer's candidate.unsupported: No source data indicates timing relative to 'this week,' nor does the record state VY1706 is Voyager's 'lead' Alzheimer's candidate.

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.